AVEO Pharma - PhIII, TIVO-1 Data and Reaction - No Surprise!
Data from TIVO-1, PhIII study (head-to-head study with ONXX’s Nexavar) of Tivozanib (formerly AV-951, partnered with Astellas) in first-line Renal Cell Carcinoma (RCC) reiterate our belief that the drug is incapable to beat the drug of choice in 1st-line, PFE’s Sutent. Safety profile was consistent with earlier study and concerns around safety may pose hurdles in the regulatory approval! With the current data showing marginal benefit vs. Nexavar, the future is not bright as it has to compete against Sutent, Nexavar (off-label), PFE’s Torisel, Roche’s Avastin, GSK’s Votrient and PFE’s Inlyta (axitinib, awaiting approval, PDUFA: Mar 13, 2012)! For more details, please read our report released on 4th January, 2012 on AVEO pharma titled “PhIII, TIVO-1 Data and Reaction - No Surprise!”
COMPANIES MENTIONED
AVEO PHARMA
AVEO PHARMA
